The insulin receptor is a heterotetrameric structure consisting of two c~-subunits of Mr 135 kilodalton on the outside of the plasma membrane connected by disulphide bonds to [3-subunits of Mr 95 kilodalton which are transmembrane proteins. Insulin binding to the c~-subunit induces conformational changes which are transduced to the ~-subunit. This leads to the activation of a tyrosine kinase activity which is intrinsic to the cytoplasmatic domains of the ~-subunit. Activation of the tyrosine kinase activity of the insulin receptor represents an essential step in the transduction of an insulin signal across the plasma membrane of target cells. Signal transduction on the post-kinase level is not yet understood in detail, possible mechanisms involve phosphorylation of substrate proteins at tyrosine residues, activation of serine kinases, the interaction with G-proteins, phospholipases and phosphatidylinositol kinases. Studies in multiple insulin-resistant cell models have demonstrated that an impaired
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Type 2 (non-insulin-dependent) diabetes mellitus is characterized by both an abnormality of insulin secretion and an insulin resistance of target tissues [1] [2] [3] [4] [5] . Cross-sectional and prospective studies suggest that insulin resistance of the skeletal muscle is one of the earliest events in the development of the disease, possibly a primary defect leading to the disease [6, 7] . To analyse the pathogenesis of cellular insulin resistance at the molecular level a detailed knowledge of the mechanism of cellular insulin action is required. In recent years substantial new insights into the mechanism of insulin signalling have been made. Insulin action consists of a wide spectrum of different effects on metabolic and growth control of the target cells of the hormone. It is believed that all these different effects are initiated by the binding of insulin to the two isoforms of the insulin receptor in the plasma membrane, whereas a branching of signal transduction occurs at a post-binding or even post-receptor level. The existence of a specific insulin receptor was postulated as early as 20 years ago by the original studies of Freychet et al. [8] , Cuatrecasas et al.
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[9] and Kono et al. [10] , who demonstrated specific saturable binding of 125I-labelled insulin to cell surfaces. Since then a large number of studies have been performed characterizing the structure and function of the insulin receptor. Major progress in the understanding of receptor function was made 9 years ago by the observation of Kasuga et al. [11] and other groups that the insulin receptor functions as a protein kinase. Meanwhile, many details about the signal flow through the receptor and about the post-receptor signalling mechanism have become known although many steps in this mechanism remain obscure. In this review present knowledge about the mechanism of transmembrane signalling through the insulin receptor kinase (IRK) shall be summarized and defects of the signal flow leading to insulin resistance in Type 2 diabetes in particular shall be discussed.
Basic characteristics of transmembrane signalling through the insulin receptor kinase
The insulin receptor is a heterotetramer comprising two o~-and two [~-subunits. The ~-subunit of 135 kilodalton (kDa) is located on the outside of the plasma membrane, It is believed that the further signal transduction occurs through tyrosine phosphorylation of other cellular proteins, which could transmit the insulin signal to the metabolic machinery of the target cell. Alternatively, it is speculated that the autophosphorylated receptor [3-subunit may interact directly with regulatory proteins or with enzymes which could be modulated in a non-covalent way. The details of this process, as understood at present, will be described in the following sections.
Functional domains of the insulin receptor (Fig. 1)
It is now clear that the insulin receptor exists in two isoforms which contain c~-subunits of either 719 or 731 amino acids [20, 21] . The insulin receptor gene contains 22 exons and it is now known that the length difference of the (xsubunit results from an alternative splicing of mRNA encoded by exon 11 [22, 23] . and threonine phosphorylation at 1348, which can inhibit the kinase activity through a conformational change. Thr 1348 seems to be a major site for phosphorylation by protein kinase C, and is probably important for regulation of receptor cell surface expression and turnover [50] . The juxtamembrane domain of the [3-subunit spanning the 12 amino acids 966-977, which shows a high degree of homology with an analogous region of the LDL-receptor is required to allow the internalization of the insulin receptor and possibly the association with specific substrate proteins in the membrane [51, 52] . Recently we obtained new data on the functional impact of the 12 amino acid peptide which determines the difference between HIR-A and HIR-B.
Beside After activation of the insulin receptor and its intrinsic kinase the further signal transmission seems to branch into several different pathways involving the systems summarized in Figure 3 .
Post-kinase signal transduction: tyrosine phosphorylated proteins (Fig. 4) For a long time the search for tyrosine phosphorylated proteins which might serve as a substrate for the insulin receptor kinase was unsuccessful. White et al. [69] were the first to use a phosphotyrosine-specific antibody to identify tyrosine phosphorylated proteins in the intact cell. They . A function of this protein in coupling the insulin receptor to phosphatidylinositol kinase was proposed. This opens the possibility of generating specific antibodies which might be valuable tools for gaining further insight into the physiological and possibly also pathophysiological role of this substrate.
Post-kinase signal transduction: insulin-stimulated serine kinase
It is believed that the insulin receptor kinase might activate another serine specific kinase which has a dual function, namely further transduction of the insulin signal to other effector systems, and in a feedback mechanism, inhibition of the first steps of the insulin signalling at the level of the insulin receptor (Fig. 5) . We, and others, have
shown that serine phosphorylation, in particular by pro-851 tein kinase C and cAMP-kinase counteracts the effects of tyrosine phosphorylation i.e. it inhibits the signalling at the level of the receptor kinase [85-90] but also at a postkinase level [91] . The physiological significance of the serine phosphorylation might therefore, be a termination of the insulin signal or a mechanism to rapidly modulate the sensitivity of cells toward insulin signals. On the other hand it has been known for a long time that a number of enzymes are regulated by insulin through phosphorylation and dephosphorylation at serine residues [58] . Therefore, a signal transduction from the tyrosine-specific insulin receptor kinase (IRK) to a serine-specific kinase must occur. The serine kinase which might fulfil both functions in the insulin signal transduction chain has not yet been identified; however, there are several possible candidates for these so called "switch kinases". Beside the 60 kDa protein described by us in fat cells [80] , several serine kinases associated with the IRK, directed against the IRK or functioning as substrates of the receptor have been described [92-97]. More recently described candidates are the ras-oncogene kinase and the so called KIK = kemptide insulin sensitive protein kinase. The latter was isolated from rat liver and serves as an insulin signal transducer to ATP citrate lyase via phosphorylation events [97] . Several lines of evidence lead also to protein kinase C functioning as a switch kinase in insulin signal transduction as we, and others, have shown that stimulation of protein kinase C mimics several of the effects of insulin [98-103].
Post-kinase signal transduction: phospholipid kinases
A phospholipid kinase activity closely associated with but distinct from the insulin receptor [104-106] has been controversial. The question was whether it is insulin-stimulated or not. However, recently an insulin stimulation of such a phosphatidylinositol-3 (PI3) kinase in the intact cell was clearly demonstrated and the functional domain of the receptor/3-subunit interacting with PI3 kinase was identified [107] . We have recently shown that both receptor isoforms HIR-A and HIR-B are able to stimulate PI3 kinase [108] . It appears possible that insulin-stimulated phospholipid phosphorylation plays a role in a signal transmitting system, which involves the activation of a phospholipase at a subsequent step, and the release of second messenger products from membrane phospholipids.
Post-kinase signal transduction: gumlosine-triphosphate (GTP)-binding proteins
A role for GTP-binding proteins in post-kinase signal transduction has long been a topic for discussion. The evidence suggesting a role for G-proteins in insulin signalling consisted of the following: an effect of insulin on ADP-ribosylation was demonstrated [109] [110] [111] , G-protein expression was found to be altered in streptozotocin-induced diabetes [112] .
Furthermore, G-proteins serve in vitro as substrates for the insulin receptor kinase [111, [113] [114] [115] . It is, however, important to note that such a role has not been observed in intact cells. Finally, G-proteins are able to modulate the insulin receptor kinase activity [111, 113] . New data have recently become available concerning the identification of G-proteins which interact with the insulin receptor. We have shown that stimulation of G-proteins produces insulin-like effects [116] and identified a 40 kDa GTP-binding site in adipocytes, with distinct characteristics from G~-(z and Gs-o~, which is activated by the insulin receptor [117] . McDonald and colleagues [118] also described a GTP-binding protein of a similar size which co-purifies with the insulin receptor. The molecular weight of this G-protein is also around 40 kDa, while a different susceptibility to cholera toxin and pertussis toxin was found. It is still unclear which effector systems might be activated by these G-proteins even though phospholipase C is a good candidate. It is, however, interesting to note that these insulin receptor associated G-proteins are able to inhibit the binding and kinase function of the insulin receptor possibly in a negative feedback sense [117] .
Post-kinase signal transduction: phospholipases and release of chemical mediators from membrane glycolipids (Fig. 6) Insulin action on phospholipase C has been a long-standing controversy. However, earlier reports on the stimulatory insulin effects on phospholipase C [119, 120] were more recently confirmed by others [121] [122] [123] . We could show that this putative insulin-activated phospholipase C is also under the negative control of protein kinase C [91] and may be activated by both receptor (HIR-A and HIR-H. U. Hfiring: The insulin receptor B) isoforms. It is believed that the substrates of these phospholipases are membrane glycolipids. By activation of the phospholipase C inositol-phosphooligosaccharides might be released from the plasma membrane. Despite many different effects of these inositol-phosphooligosaccharides on isolated cells and enzymes which have been described [124] [125] [126] [127] [128] [129] [130] [131] [132] , their physiological role is still being discussed. As most of these glycolipids are located on the outside of the cell [132] this system might not be involved in intracellular signalling but might be important for cellcell signalling. Unfortunately even now exact structural data on these putative insulin second messengers are missing.
Signal transduction to the glucose transport system: the fat cell model
Despite increasing knowledge about the post-kinase signalling systems described above, the exact mechanism linking the insulin receptor to particular effector systems remains obscure.
One of the most important and intensively studied effector system of the insulin signal is the glucose transport system. Due to the work of Birnbaum et al. [133] , Miickler et al. [134] , Bell et al. [135] and others it is clear that five different isoforms of the glucose transporter protein exist. A classic cell model which was widely used to study the signal flow from the receptor to the glucose transport system is the isolated adipocyte where activation and deactivation of the glucose transport system can be easily studied [136, 137] . Almost 10 years ago it was shown in this cell model by Cushman et al. [138] and Kono et al. [139] that insulin induces a translocation of glucose carriers from intracellular membranes to the plasma membrane. In the meantime data from many different groups, including our own, have suggested that a purely translocation model is not sufficient to explain the insulin effect [99, 116, [140] [141] [142] [143] [144] . We, and others, suggest a combined model involving translocation and activation of the glucose carriers where separate signalling chains activate both steps [144] . We have used several insulin-like acting pharmacological tools to test which post-kinase signal transducers might be involved in the insulin signal from the receptor to the translocation step or the activation step. The effects of these pharmacological tools are shown in Figure 7 . We have found that the insulin effect on glucose carrier translocation can be mimicked by phorbol esters [99, 102, 103]. As phorbol esters activate the protein kinase C it is very likely that protein kinase C might be somehow involved in the signal between the receptor and the translocation process. Recently, we found that the phorbol ester effect is restricted to the translocation of GLUT-4 [102], not GLUT-1 suggesting a distinct translocation machinery for both carrier types [103] . We used other pharmacological tools to test which signal transducing elements could be involved in the second signal transmitting chain leading from the insulin receptor to carrier activation. As aluminium chloride [116] , exogenously added phospholipase C [116] and a mixture of exogenously added inositolphosphooligosaccharides [144, 145] can all mimick the insulin effect on carrier activity, it might be speculated that the carrier activating signal transmission involves a sequence of G-proteins, phospholipase C, and the release of inositol-phosphooligosaccharides.
Location of defects in the insulin signalling chain: insulin receptor kinase defects as a possible cause of cellular insulin resistance
The above-described mechanisms of insulin signal transduction can be used as a basis to discuss the molecular mechanisms leading to cellular insulin resistance. Cellular insulin resistance can be caused by defects at each level of the signal transmitting chain. At the level of the receptor kinase itself a number of 'defects' or 'inactive states' have been found in several model systems of insulin resistance, which provided the basis for later studies in insulin sensitive tissues of Type 2 diabetic patients.
another animal model, goldthioglucose-treated insulinresistant mice, LeMarchand et al. [148] have shown decreased IRK activity in skeletal muscle. The same group [153] also found a reduced kinase activity in skeletal muscle of genetically obese mice. We (unpublished observation) and others [154, 155] have not found this defect in ob/ob mice, which suggests the possibility that it might be restricted to certain strains of these mice. Interestingly, reduced kinase activity has also been shown in insulinopoenic states. Kadowaki et al. [149] have shown decreased receptor autophosphorylation in the livers of streptozotocin-diabetic rats and Burant et al. [156] have shown structural and functional alterations of the kinase in skeletal muscle of the same animals. In summary, these data in animal models pointed towards a crucial role of skeletal muscle IRK in the pathogenesis of insulin resistance and prompted us to concentrate in later studies of Type 2 diabetic patients on the IRK of this tissue.
The syndromes of severe insulin resistance in human subjects
Important information has also come from the study of blood cells and fibroblasts from patients with the syndrome of severe type A insulin resistance [157] [158] [159] . Different phenotypes of insulin receptor defects exist in this syndrome with reduced insulin binding, normal insulin binding but reduced IRK, or a combination of both defects [159] . Recently insulin receptors from several patients were cloned and the amino acid exchanges leading to the different forms of receptor defects have been identified [160] [161] [162] [163] [164] [165] which has substantially increased the understanding of structure and functional domains of the insulin receptor.
In vitro models and animal models
The first cell model which showed an association between a reduced kinase activity and an insulin-resistant state was an insulin-resistant variant of a mouse melanoma cell line [146] . Even though no causal relationship could be proven between the reduced insulin receptor kinase activity in the insulin-resistant cells and the appearance of insulin resistance, this study gave a first hint that defects of the IRK might be involved in the pathogenesis of some forms of cellular insulin resistance. Important information came later from the study of IRK in skeletal muscle, liver and fat of rat and mouse models resembling some features of Type 2 diabetes in humans [147] [148] [149] [150] . The obese diabetic Zucker rat is an animal model which has many features in common with an early phase of Type 2 diabetes in humans [151, 152] . These animals are insulin resistant and clearly show elevated insulin levels. Insulin resistance of the target tissues of insulin action, especially skeletal muscle, has been demonstrated [152] , and we found insulin insensitivity of the receptor kinase of skeletal muscle [147] . In contrast we could find no kinase defect in the livers of these animals, while Debant et al. [150] even reported a hyperresponsive kinase in adipose tissue in young animals. In
In vitro induced insulin resistance: the IRK modulators (Table 1) The above-described models of cellular insulin resistance clearly demonstrate that IRK defects are associated with cellular insulin resistance and that IRK defects are an important pathophysiological mechanism leading to cellular insulin resistance. More detailed information about the mechanisms whereby the IRK can become inactive has been obtained from the study of cells where insulin resistance was induced in vitro. These studies have shown that the IRK-activity is under the control of modulator systems. Activation of inhibitory modulators might be an important mechanism causing insulin resistance through an inactive IRK. Some examples of these modulators shall be discussed in more detail. Catecholamines can induce an insulin resistance of the glucose transport system of isolated rat and human adipocytes in vitro [85, 87, 166] . We and others have shown that this insulin resistance correlated with an inhibition of the receptor kinase [85, 87, 167, 168] .
In our study the insulin receptor isolated from these cells showed a more than 90 % inhibition of the IRK measured in vitro [85], if a low ATP concentration was used in the in vitro phosphorylation assay. We found that a change of the affinity of the ATP binding site had occurred. Thus, it appears that catecholamine treatment can inhibit the insulin receptor tyrosine kinase through modulation of its ATP binding site. Recently a method to determine in vivo kinase activity has been used by Klein et al. [167] to show that the in vitro alteration described above correlates with a reduced kinase activity in the intact cell. It is speculated that this catecholamine-induced modulation of the receptor kinase occurs through serine phosphorylation of the insulin receptor [3-subunit by the cyclic AMP dependent-kinase (cAMP-kinase). Phosphorylation of the [3-subunit by the cAMP-kinase was at least shown in vitro by Roth et al. [169] . Tanti et al. [168] have also demonstrated an in vitro inhibition of the insulin receptor kinase by cAMP-kinase, but no phosphorylation was found. The site of phosphorylation has not yet been identified, although phosphorylation of the C-terminal tail is most likely (see below).
More important for the pathogenesis of insulin resistance than cAMP-dependent kinase might be protein kinase C. Protein kinase C-stimulating phorbol esters are able to induce in vitro insulin resistance of isolated adipocytes [86, 89] as well as FAO-hepatoma cells [88] [89] [90] . The IRK isolated fl'om phorbol ester-treated cells showed reduced activity in vitro [86] , and an altered affinity to ATP [86] . The mechanism which leads to the inhibition of the IRK is again likely to be serine phosphorylation of the insulin receptor. Thus, Jacobs et al. [88] and Takayama et al. [89, 90] reported that phorbol ester stimulation leads to a serine phosphorylation of the insulin ~-subunit in the intact cell. Takayama et al. [90] have recently shown that this serine phosphorylation is due to activation of protein kinase C, and that the inhibitory serine phosphorylation occurs at the C-terminal tail of the receptor [90] . The models of catecholamine and phorbol ester-induced insulin resistance showed that serine phosphorylation of the insulin receptor functions as an inhibitory mechanism. The mechanism might also be important in some other states of cellular insulin resistance. An important example is hyperglycaemia-induced insulin resistance.
Hyperglycaemia induces insulin resistance in isolated fat cells and this coincides with an inhibition of the IRK [171] [172] [173] . As simultaneously an increased protein kinase C activity is found [171] [172] [173] [174] [175] it appears likely that hyperglycaemia-induced insulin resistance is associated with an IRK-inhibition through serine phosphorylation by protein kinase C. This hypothesis is further supported by the observation that inhibitors of protein kinase C are able to suppress the inhibitory effect of glucose [173] . Another pathophysiologically important modulator is hyperinsulinaemia. The mechanism of IRK inhibition is, however, unclear [176] and it is not known whether insulin concentrations within the physiological range can induce an inhibition of the receptor kinase. A possible role of the membrane environment in inducing kinase resistance has recently been demonstrated in studies where the crucial role of phospholipids for kinase activity was shown [170, 177] . It is tempting to speculate that alterations of membrane lipids might be a factor causing decreased kinase activity in disease states. Other in vitro H. U. Hhring: The insulin receptor factors regulating the kinase are adenosine [179] and polylysine, which activate the kinase in vitro against exogenous substrates [178] . There are also soluble inhibitor peptides, however, the physiological function remains unclear [181] . Thyroid hormones are also able to influence the IRK [182, 183] . Furthermore, an inhibitory effect of gamma -S-GTP can be demonstrated in fat cell membranes suggesting a modulating function of a receptor associated G-protein [117] . It is interesting to speculate that altered expression or function of these G-proteins might be an important cause of cellular insulin resistance in disease states.
IRK in insulin target tissues of Type 2 diabetic patients
The studies described have shown that a kinase defect is apparently one possible cause of cellular insulin resistance. Furthermore, modulators causing an inactive state of the kinase in vitro have been described. On this basis we and others have investigated whether a kinase defect or an inhibitory modulation of the IRK plays a role in the pathogenesis of Type 2 diabetes. Several studies with tissue from Type 2 diabetic patients have now been conducted ( Table 2) . Freidenberg et al. [184] studied fat cells of Type 2 diabetic patients and were the first to find in vitro insulin insensitivity and unresponsiveness of the IRK isolated from cells of Type 2 diabetic patients. The authors concluded that in Type 2 diabetic patients a coupling defect between insulin binding and activation of the tyrosine kinase exists. The study does not provide information about the insulin receptor in intact fat cells. It was subsequently shown that this kinase defect is partially reversed after weight loss in these patients [185] . As a mechanism of the kinase defect an altered proportion of active and inactive receptors was proposed [185] . Caro et al. [186] found a similar defect in liver. Skeletal muscle, probably the most important tissue in the pathogenesis of Type 2 diabetic patients was also studied by Caro et al. [187] , Arner et al. [188] and by ourselves [147, 189] .
We and Arner have found a kinase defect or inactivity in the skeletal muscle of Type 2 diabetic patients as described below. Contrary to this Caro et al. [186] have found no Type 2 diabetes-specific kinase defect. More recently a reduced IRK-activity was also described in the skeletal muscle of Type 2 diabetic Pima Indians [198] . Possible reasons for these discrepant findings are discussed elsewhere in detail [12] . Briefly, it is possible that the different localisation of the skeletal muscle, i. e. different fibre composition, is important. Another possible explanation might be provided by the different patient characteristics, i.e. body mass index and insulin levels. Our results comparing IRK from non-obese Type 2 diabetic patients and non-obese control subjects, isolated as described earlier [190] , may be summarized as follows. No difference in insulin binding was found. However, a shift of the insulin dose response curve to the right was apparent, and there was a significant reduction of the maximal activity of 40--50 % in autophosphorylation and of 50-60 % in GLUT-4: Tyrl substrate phosphorylation. These results are in good agreement with the results of Arner et Freidenberg [184] Caro [186] Caro [187] Arner [188] Present author [147, 189] Bulangu [198] Note: ND, not determined; 1", increased; -1,, decreased; --+, unchanged al. [188] concerning the receptor kinase from non-obese control subjects and non-obese Type 2 diabetic patients. The conclusion from our own study and that of Arner et al. [188] was that the receptor kinase of skeletal muscle is defective in Type 2 diabetic patients. Considering these data it is important to note that Arner et al. [188] have shown that obesity itself already decreases kinase activity. It is thus possible that in extremely obese patients the kinase is already depressed to an extent which makes it impossible to detect an additional effect in Type 2 diabetic patients. While the depressed IRK of fat cells is partially reversible after weight loss, it is interesting to note that the decreased IRK of skeletal muscle is found independently of the weight and the metabolic situation of the patients. Therefore, it seems possible that a reduced kinase activity of the skeletal muscle might be a "primary defect" found in a population at high risk of developing obesity or Type 2 diabetes while the IRK inactivity found in other tissues might be merely a secondary event due to modulator effects, for instance hyperglycaemia-induced serine phosphorylation by protein kinase C or another secondary modulation event.
What is the molecular mechanism causing the reduced kinase activity of the skeletal muscle in non-obese Type 2 diabetic patients? There is no conclusive answer to this question at present. However, our studies of skeletal muscle IRK including the tryptic peptide mapping of the phosphorylated [3-subunit suggest the possibility that the recently proposed autoactivation cascade of the IRK [41] might be disturbed in diabetic patients [189] . The diabetic kinase obviously does not proceed to the fully active triphosphorylated form, as in the case of the kinase from non-diabetic control subjects [189] . If this observation is combined with the recent findings in adipose tissue from Type 2 diabetic patients [185] , it might be speculated that the proportion of receptors converting to the triphosphorylated form is reduced in Type 2 diabetic patients.
Further studies will have to answer the questions as to whether the reduced kinase activities, which were found in vitro, are also relevant in the intact cell.
What is the contribution of an IRK defect to the pathogenesis of Type 2 diabetic patients
A reduced IRK activity was found in the target tissues of insulin action in Type 2 diabetic patients [184] [185] . It is likely that this kinase inactivity is a pathophysiologically relevant factor in the development of the insulin resistance. Other defects might be located at the point of signalling to glycogen synthetase and in the glucose carrier system. However, it is not clear whether IRK inactivity reflects a primary defect or represents a secondary event in the development of this disease. It is clear that genetic factors contribute to the predisposition to the development of Type 2 diabetes and it has been demonstrated, that insulin resistance of the major target tissues of insulin action plays an important role in the pathogenesis of this disease. One of the multiple candidate genes possibly involved in the pathogenesis of Type 2 diabetes might be the gene for the insulin receptor. However, all of the above-mentioned structural defects of the receptor [157] [158] [159] [160] [161] [162] [163] [164] [165] caused extreme insulin resistance. On the other hand it is interesting that some patients with extreme insulin resistance have relatives in whom the heterozygosity for the mutated receptor gene is associated with moderate insulin resistance similar to that found in Type 2 diabetic patients [191] . Even though these are interesting data there is at present no proof from genetic studies that genomic polymorphisms of the insulin receptor gene are significantly associated with Type 2 diabetic patients [192, 193] . We investigated exon 20 of the receptor gene from Type 2 diabetic patients with severe alterations of the autophosphorylation cascade and found no mutation [194] . Other groups could not demonstrate genetic defects of the insulin receptor in diabetic Pima Indians [195] but could show an increased risk for gestational diabetes mellitus associated with insulin receptor and insulin-like growth factor-II restriction fragment length polymorphisms [196] .
In summary, there is no strong evidence for a primary inactivity of the IRK due to a sequence abnormality of the receptor protein itself. If it is still assumed, for the reasons discussed above, that skeletal muscle IRK inactivity be-longs to early events in the pathogenesis of the disease a primary "modulator abnormality" might be a more likely explanation. Furthermore, we recently observed that the expression of the receptor isoforms HIR-A and HIR-B is altered in the skeletal muscle of Type 2 diabetic patients [197] . Further studies are now required to evaluate whether this phenomenon is a primary event related to the development of insulin resistance or whether this alteration compensates for a defect at another level of the insulin signalling chain. 
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